---
title: "Pharmaron Shareholders Approve 2025 AGM Resolutions, Dividend Plan and Governance Changes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289607761.md"
description: "Pharmaron Beijing Co., Ltd. (HK:3759) shareholders approved all resolutions at the 2025 AGM, including dividend plans, director remuneration, auditor appointments, and governance amendments. The meeting validated the election of a non-executive director and reinforced the company's governance framework. Analysts maintain a 'Buy' rating with a HK$28.10 price target for the stock."
datetime: "2026-06-12T13:41:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289607761.md)
  - [en](https://longbridge.com/en/news/289607761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289607761.md)
generator: "portal-rs"
---

# Pharmaron Shareholders Approve 2025 AGM Resolutions, Dividend Plan and Governance Changes

Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an update.

Pharmaron Beijing Co., Ltd. reported the results of its 2025 annual general meeting in Beijing, confirming that the meeting was validly convened under PRC law and its Articles of Association, with about 48.7% of voting shares represented. All directors attended, and independent scrutineers, including the H share registrar and the company’s PRC legal adviser, supervised the poll process in line with Hong Kong listing requirements.

Shareholders approved all ordinary resolutions, including the 2025 profit distribution and 2026 interim dividend plan, the 2025 annual report and results, director remuneration and a new remuneration policy, an estimated hedging quota for 2026, and the appointment of domestic and international auditors. The meeting also endorsed the election of a non-executive director to the fourth board and amendments to the Articles of Association, reinforcing Pharmaron’s governance framework and capital management plans for the coming year.

The most recent analyst rating on (HK:3759) stock is a Buy  
 with a HK$28.10 price target.  
 To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock,  
 see the HK:3759 Stock Forecast page. 

**More about Pharmaron Beijing Co., Ltd. Class H**

Pharmaron Beijing Co., Ltd. is a China-based contract research and development services provider to the pharmaceutical and biotech industries, listed in Hong Kong with both A shares and H shares. The company focuses on offering integrated R&D and related services to global drug developers, positioning itself as a key player in the life sciences outsourcing market.

**Average Trading Volume:** 5,657,171

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$41.76B

### Related Stocks

- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)

## Related News & Research

- [Pharmaron Beijing announces extraordinary general meeting, H share class meeting](https://longbridge.com/en/news/296918409.md)
- [Pharmaron Beijing Co., Ltd. Class H (17Q1) was downgraded to a Hold Rating at UBS](https://longbridge.com/en/news/296967052.md)
- [Tianjin Construction Development amends articles of association after shareholder vote](https://longbridge.com/en/news/296362801.md)
- [BaTeLab Shareholders Approve Amendments to Articles at 2026 EGM](https://longbridge.com/en/news/296789818.md)
- [Luxshare Precision Calls EGM to Revise Governance Rules and Approve Bond Issuance](https://longbridge.com/en/news/296834492.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**